OXFORD, Miss., March 29, 2007 (PRIME NEWSWIRE) -- Insight Medical Group, a bioscience technology development and acquisition company specializing in the accurate detection of cancer, announced today it has appointed Dr. Harvey Bialy, Ph.D., to its Board of Advisors.
Bialy graduated first in his class from Bard College in 1966, and was awarded a Ph.D. in molecular biology in 1970 by the University of California at Berkeley. He is the founding scientific editor of Nature Biotechnology (part of the Nature family of publications), and edited its peer-reviewed content from 1983-1996. He has coauthored significant papers in molecular genetics -- among them being the first to show that phage genes can subvert host functions (Lindahl 1970, Sironi 1971). He has also authored editorials and commentaries on contemporary issues in biotechnology in Nature Biotechnology and other leading journals.
Bialy was a resident scholar of the Institute of Biotechnology (IBT) of the National Autonomous University of Mexico (UNAM) in Cuernavaca between 1996 and 2006, where he also founded and directed the Virtual Library of Biotechnology for the Americas.
Bialy authored Oncogenes, Aneuploidy, and AIDS, (ISBN 1556435312) a book about the scientific life of fellow molecular biologist Peter Duesberg, with special emphasis on Duesberg's aneuploidy theory of cancer and on the politics of modern science.
He was the co-recipient (with Stanley Falkow of Stanford University School of Medicine) of a grant from the Charles Merill Trust to study antibiotic resistant pathogens in Nigeria in 1978. Bialy received a World Health Organization grant to study the epidemiology and genetics of antibiotic resistant enteric pathogens, also in Nigeria, in 1982. He worked as a visiting researcher or research fellow at several universities in the United States and Africa throughout the 1980s and 1990s. He was advisor to the Center for Biotechnology and Genetic Engineering in Havana, Cuba from 1986-1996.
He has served on many international and government advisory panels and has been a long-time supporter of the chromosomal theory of cancer.
Anthony Welch, Chairman, said: "Today's announcement is the first of several appointments. Harvey Bialy is a powerful addition to the organization and we could not be more pleased."
Mr. Bialy said: "The science behind the company's cancer detection technology is impeccable. In the past decade, the aneuploidy theory of cancer has proved correct both experimentally and theoretically in numerous, rigorously peer reviewed publications in the best journals. I am extremely honored to be a member of Insight Medical's board of scientific advisors."
About the AnuCyte Cancer Detection System
The AnuCyte Cancer Detection System is an automated machine to detect the presence of cancer in cell samples. The system accurately identifies cancer at any stage in its development and also identifies healthy cancer-free cells in the same test within the same sample. For a White Paper on the system and the science, you may acquire a copy from this link: http://www.insightmedicalgroup.com/library/IMG_White_Paper.pdf
About AnuCyte's Inventors:
The inventor of the AnuCyte system, Dr. David Rasnick, Ph.D. and his scientific research collaborator, Dr. Peter Duesberg, Ph.D., have been prominent names internationally for many years for their research and publications. On many occasions both have appeared internationally on television, in magazines, newspapers and scientific publications. Peter Duesberg is author of the widely available book: "Inventing the AIDS Virus."
In 1970, Peter Duesberg isolated the first cancer gene through his work on retroviruses and mapped the genetic structure of these viruses. This and his subsequent work in the same field resulted in his election to the National Academy of Sciences in 1986. He was also the recipient of a seven-year Outstanding Investigator Grant from the National Institute of Health. He has been invited to become a Honorary Member of the World Innovation Foundation alongside 91 Nobel Laureates. (www.thewif.org.uk)
About Insight Medical Group and Modern Technology Corp
Insight Medical Group, a wholly-owned subsidiary of Modern Technology Corp, is a specialized biosciences development company whose mission is to bring world-changing medical technology and research to market in the areas of cancer and AIDS. The AnuCyte Cancer Detection System was invented by Dr. David Rasnick, Ph.D. The technology behind AnuCyte and the chromosomal imbalance theory is the result of 45 years of combined cancer research by Dr. David Rasnick, Ph.D. and Dr. Peter Duesberg, Ph.D., who continues his studies on cancer research at the University of California, Berkeley. Modern Technology Corp, a bioscience technology development and acquisition company, builds revenues through a model continuous growth, strategic acquisitions, and commercialization of nascent technology. MODC is a fully-reporting public company with the U.S. Securities and Exchange Commission. For the company's SEC filings, visit www.sec.gov. The company's web address is: http://www.moderntechnologycorp.com
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.